Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 1
2007 5
2008 2
2009 3
2010 2
2011 1
2012 1
2013 3
2014 3
2015 2
2016 2
2018 3
2019 3
2020 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Using CTCs for pharmacogenomic analysis.
Hart CD, Galardi F, Pestrin M, De Luca F, Risi E, Di Leo A. Hart CD, et al. Among authors: pestrin m. Pharmacol Res. 2016 Apr;106:92-100. doi: 10.1016/j.phrs.2016.02.019. Epub 2016 Feb 24. Pharmacol Res. 2016. PMID: 26921662 Review.
The role of abemaciclib in treatment of advanced breast cancer.
McCartney A, Moretti E, Sanna G, Pestrin M, Risi E, Malorni L, Biganzoli L, Di Leo A. McCartney A, et al. Among authors: pestrin m. Ther Adv Med Oncol. 2018 May 31;10:1758835918776925. doi: 10.1177/1758835918776925. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29899762 Free PMC article. Review.
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach.
Fontanella C, Giorgi CA, Russo S, Angelini S, Nicolardi L, Giarratano T, Frezzini S, Pestrin M, Palleschi D, Bolzonello S, Parolin V, Haspinger ER, De Rossi C, Greco F, Gerratana L. Fontanella C, et al. Among authors: pestrin m. Crit Rev Oncol Hematol. 2022 Dec;180:103848. doi: 10.1016/j.critrevonc.2022.103848. Epub 2022 Oct 17. Crit Rev Oncol Hematol. 2022. PMID: 36257536 Free article. Review.
The continued evidence from overviews: what is the clinical utility?
Turner N, Biganzoli L, Malorni L, Migliaccio I, Moretti E, Pestrin M, Sanna G, Siclari O, Di Leo A. Turner N, et al. Among authors: pestrin m. Breast. 2013 Aug;22 Suppl 2:S8-11. doi: 10.1016/j.breast.2013.07.002. Breast. 2013. PMID: 24074798 Free article. Review.
Taxanes in the elderly: can we gain as much and be less toxic?
Biganzoli L, Licitra S, Moretti E, Pestrin M, Zafarana E, Di Leo A. Biganzoli L, et al. Among authors: pestrin m. Crit Rev Oncol Hematol. 2009 Jun;70(3):262-71. doi: 10.1016/j.critrevonc.2008.07.017. Epub 2008 Aug 30. Crit Rev Oncol Hematol. 2009. PMID: 18762431 Review.
Using specific cytotoxics with a targeted mind.
Di Leo A, Claudino WM, Pestrin M, Licitra S, Biganzoli L. Di Leo A, et al. Among authors: pestrin m. Breast. 2007 Dec;16 Suppl 2:S120-6. doi: 10.1016/j.breast.2007.07.021. Epub 2007 Aug 27. Breast. 2007. PMID: 17720501 Review.
Adjuvant chemotherapy: which patient? What regimen?
Turner N, Biganzoli L, Malorni L, Migliaccio I, Moretti E, Pestrin M, Sanna G, Siclari O, Di Leo A. Turner N, et al. Among authors: pestrin m. Am Soc Clin Oncol Educ Book. 2013:3-8. doi: 10.14694/EdBook_AM.2013.33.3. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714442 Free article.
33 results